These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 17852450

  • 21. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
    Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, Kim DH, Sohn SK, Lee JJ, Suh C.
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
    [Abstract] [Full Text] [Related]

  • 22. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
    Tichý M, Maisnar V, Palicka V, Friedecký B, Vávrová J, Novotná H, Cermáková Z, Dastych M, Cechák P, Vogtová D, Jarolímková E, Benáková H, Hachová L, Bezdícková D, Kouril F, Zábranská EA, Zenková J, Slabý P, Scudla V, Gregora E, Spicka I, Straub J, Schützova M, Hájek R.
    Neoplasma; 2006 Aug; 53(6):492-4. PubMed ID: 17167717
    [Abstract] [Full Text] [Related]

  • 23. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R, Redaelli S, Maino C, Bertuol S, Costantini C, Lazzarini A, Brivio L, Gorini M.
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [Abstract] [Full Text] [Related]

  • 24. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [Abstract] [Full Text] [Related]

  • 25. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
    Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimopoulos MA, Greek Myeloma Study Group, Greece.
    Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
    [Abstract] [Full Text] [Related]

  • 26. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
    Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.
    Hematol Oncol; 2018 Dec; 36(5):792-800. PubMed ID: 30176173
    [Abstract] [Full Text] [Related]

  • 27. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
    Bila J, Jelicic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, Antic D, Mihaljevic B.
    Oncol Res Treat; 2017 Dec; 40(10):616-620. PubMed ID: 28950269
    [Abstract] [Full Text] [Related]

  • 28. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF, Bessmel'tsev SS, Abdulkadyrov KM, Blinov MN, Stel'mashenko LV.
    Ter Arkh; 1996 Dec; 68(10):28-31. PubMed ID: 9026938
    [Abstract] [Full Text] [Related]

  • 29. [Clinical features and survival of Chilean patients with multiple myeloma].
    Conté L G, Figueroa M G, Lois V V, Cabrera C ME, León R A, García L H, Rojas R H.
    Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
    [Abstract] [Full Text] [Related]

  • 30. A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.
    Iriuchishima H, Saitoh T, Handa H, Isoda A, Matsumoto M, Sawamura M, Iwasaki A, Ushie C, Hattori H, Sasaki Y, Mitsui T, Yokohama A, Tsukamoto N, Murakami H, Nojima Y.
    Eur J Haematol; 2015 Feb; 94(2):145-51. PubMed ID: 24981274
    [Abstract] [Full Text] [Related]

  • 31. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
    Scudla V, Petrová P, Minarík J, Pika T, Budíková M, Bacovský J, Repovský S.
    Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
    [Abstract] [Full Text] [Related]

  • 32. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
    Goldsmith SR, Fiala MA, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Schroeder MA, Tomasson M, Wildes TM, Vij R.
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
    [Abstract] [Full Text] [Related]

  • 33. [Prognositic factors in multiple myeloma].
    Nagura E.
    Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
    [Abstract] [Full Text] [Related]

  • 34. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P.
    J Clin Oncol; 2015 Sep 10; 33(26):2863-9. PubMed ID: 26240224
    [Abstract] [Full Text] [Related]

  • 35. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.
    Dimopoulos MA, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas K, Terpos E, Greek Myeloma Study Group.
    Ann Oncol; 2012 Mar 10; 23(3):722-729. PubMed ID: 21652580
    [Abstract] [Full Text] [Related]

  • 36. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma.
    Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR.
    Semin Hematol; 2009 Apr 10; 46(2):110-7. PubMed ID: 19389494
    [Abstract] [Full Text] [Related]

  • 37. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
    Li J, Wu XB, Zhou Y, Wang X, Chen JX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug 10; 20(4):926-9. PubMed ID: 22931656
    [Abstract] [Full Text] [Related]

  • 38. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
    D'Anastasi M, Notohamiprodjo M, Schmidt GP, Dürr HR, Reiser MF, Baur-Melnyk A.
    AJR Am J Roentgenol; 2014 Oct 10; 203(4):854-62. PubMed ID: 25247952
    [Abstract] [Full Text] [Related]

  • 39. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
    Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA.
    Blood; 1990 Feb 15; 75(4):823-30. PubMed ID: 2405920
    [Abstract] [Full Text] [Related]

  • 40. Tumor load in patients with multiple myeloma: β₂-microglobulin levels versus low-dose whole-body CT.
    Pfahler V, D'Anastasi M, Dürr HR, Schinner R, Ricke J, Baur-Melnyk A.
    Eur J Haematol; 2020 May 15; 104(5):383-389. PubMed ID: 31762076
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.